Chief Executive Officer

Dr. Andrew Potter

Chief Executive Officer

Dr. Andy Potter first joined VIDO in 1985 as a research scientist when he was recruited from Health Canada in Ottawa. In 1994 he was appointed as VIDO’s Associate Director of Research. Since 2007 he has been the CEO and Director of VIDO.

In 2011, Dr. Potter was elected a Fellow of the Canadian Academy of Health Science (CAHS). The CAHS works in partnership with the Canadian Academy of Engineering and the Royal Society of Canada to form the Council of Canadian Academies. Comprised of Canada's leading minds in health research and practice, the Council provides assessments and advice on key issues relevant to the health of Canadians. Dr. Potter has served on a number of public and private sector committees, and has been instrumental in transferring technology from the VIDO laboratories to the private sector. He interacts frequently with major animal health companies and serves as a consultant to numerous smaller ones.

Dr. Potter is internationally recognized for his visionary research into how bacteria cause disease. His work at the interface of human and animal health has bolstered VIDO-InterVac's international reputation in this critical area of research. His ground-breaking projects have contributed to several "world firsts", including the world's first genetically engineered animal vaccine.

He currently runs a successful research program that is well-funded by competitive grants at the national level. Recently, he has been working on the application of genomics to the animal health field and is forging links between the animal and human infectious disease research communities to ensure that technologies common to both fields can be leveraged to their greatest benefit.

Dr. Potter completed his undergraduate studies at CARLETON University and received his Ph.D. in microbiology from the University of Otago (New Zealand) in 1981.

He has mentored more than 30 graduate students and post-doctoral fellows who currently hold positions in industry, academia and government worldwide. He has also contributed to more than 50 patents for human and animal vaccines and therapeutics.

Chief Operating Officer

Dr. Luis Martin

Chief Operating Officer

Dr. Luis H. Martin is the Chief Operating Officer and is responsible for managing the development of specific vaccine projects. He brings to the group over 20 years of experience in commercial biotechnology. Prior to joining PREVENT, Dr. Martin was Chief Development and QA Officer at Mitomics where he was responsible for managing new product development, the clinical trial programs, and directing the implementation of a Quality Assurance program. Previously he was also the managing director and founder of Lumar Management Consulting Inc. (LMCI), a company providing operational management and executive mentoring to emerging biotechnology companies.

Dr. Martin has also held various senior management positions at biotechnology companies including, Director of Research and development at Arius Research Inc.; Vice President, Research and Development at GENSEL Biotechnologies Inc.; and Director of Immunobiology at Biomira Inc. He also previously served as Section Head of Molecular Immunology with the NRC Biotechnology Research Institute in Montreal, and held adjunct faculty appointments with the Department of Pharmacology and Therapeutics at McGill University, and the Department of Molecular Biology and Genetics at the University of Guelph.

Dr. Martin holds a Ph.D. in biology from the University of Waterloo, an M.Sc. and B.Sc. in cell biology from the University of Toronto, and completed post-doctoral studies at the Medical Research Council in Cambridge, UK under Dr. Cesar Milstein, FRS, and Nobel Laureate.

Director, Communications and External Relations

Peter Yim

Director, Communications and External Relations

Mr. Peter Yim joined PREVENT as the Director of Outreach and Partnerships in 2008. In this capacity he is responsible for building awareness of, developing relationships with, and providing marketing support for academia, industry, governments, international non-governmental organizations and private sector partners. Through partnership building and understanding, research companies, corporations, foundations and the public healthcare sector can more effectively work together to provide vaccines to address Canadian public health priorities.

Mr. Yim also fosters and facilitates initiatives that provide the organization with focus and the capacity to harness funding opportunities that will ensure PREVENT's long term sustainability. This includes engaging the services of external parties with expertise in partnership development, where necessary. In 2013, Mr. Yim was appointed as the Vice President of Communications and External Relations.

Mr. Yim was born in Shanghai, China, and was raised in Hong Kong. Upon finishing high school, he moved to Austin, Texas, where he attended the University of Texas and received a Bachelor of Business Administration (BBA) degree. After returning to Hong Kong, Mr. Yim took a position with a textile company as an international sales and marketing representative.

In 1978, Mr. Yim came to Canada and was hired by Merck Sharp and Dohme as a professional service representative. In 1982, the company expanded and created the Merck Frosst Division and Mr. Yim was recruited to join the new venture. In 1983, he was promoted to the position of Hospital Specialist Representative and subsequently, to senior hospital representative, focusing on infectious diseases and antibiotics.

In 1996, Mr. Yim joined the Merck Vaccine Division and promoted a number of novel vaccine products, during which time he received the highest award in the Division for outstanding performance. In 1998, Mr. Yim was further promoted to the position of Regional Business Manager (Western Canada), leading, motivating, and developing direct reports to aspire to higher levels of competency and success, establishing benchmarks of excellence to build stellar relationships with both internal and external customers.

From 2003- 2007, Mr. Yim was a Medical Science Liaison in the Merck Frosst Cardiovascular Division and subsequently the Urology Division, developing profiles and identifying areas of professional interest to motivate a change in perception amongst stakeholders and key opinion leaders.

Business Development Manager and Project Manager

Dr. John Mapletoft

Business Development Manager and Project Manager

Dr. John Mapletoft is the Business Development Manager for PREVENT. Dr. Mapletoft has been a part of the Commercialization and Product Development teams at PREVENT since 2009. In this capacity he is tasked to prospect, evaluate, negotiate and maintain agreements and strategic alliances with third parties. He also plays a pivotal role in supporting ongoing Product Development activities at PREVENT.

Dr. Mapletoft has been working with vaccines for more than 10 years. He received a B.Sc. Honours in Biochemistry and a Ph.D. in Veterinary Microbiology from the University of Saskatchewan in Saskatoon. Over the course of his Ph.D., he carried out research on vaccines and adjuvants at the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) in Saskatoon, Saskatchewan. In particular, his Ph.D. research focused on the use of novel adjuvants to modulate the immune response induced by vaccines against Respiratory Syncytial Virus (RSV). He has a strong background in the design and execution of pre-clinical animal studies.

Dr. Mapletoft is also a graduate of the WestLink Innovation Network Technology Commercialization Internship Program, in which he spent time working with PREVENT and Ag-West Bio Inc. in Saskatoon, as well as Red River College’s Applied Research & Commercialization Office and the Public Health Agency of Canada (PHAC)-National Microbiology Laboratory’s Business Development & Operations Office in Winnipeg, Manitoba. His training during the Internship Program focused primarily on agreements, intellectual property management and financing activities, all in the context of technology commercialization.

Project Manager

Dr. Elodie Pastural

Project Manager

Élodie Pastural, PhD, RAC, CAPM, is a Product Development Project Manager within PREVENT.

Élodie Pastural first graduated as an engineer from the École Polytechnique, a prestigious science and engineering school in France. She then pursued medical research through an MSc and a PhD in Immunology from University Paris VI / Pasteur Institute. Following a first post-doctoral fellowship in biochemistry funded by the EMBO at the Institute of Biology and Chemistry of Proteins in Lyon she moved to Canada because of her spouse’s job transfer. After completing a CIHR-funded post-doctoral training in biochemistry at the University of Saskatchewan, Dr. Pastural became a research scientist at Phenomenome Discoveries Inc. in the metabolomics field, in charge of the identification of metabolic patterns associated with cancers and neurodevelopmental disorders. Since July 2011 she has been a project manager with PREVENT, focusing on the development of promising Canadian vaccine candidates. She is certified in both Project Management and Regulatory Affairs and recently earned the RAC (US) credential which will consolidate PREVENT’s regulatory expertise.